The reverse acquisition company Hunter Capital RTO1 has entered into a non-binding letter of intent regarding a planned reverse acquisition of Resother Pharma, which is a Nordic clinical-stage biotechnology company with a new drug candidate in Phase 2 targeting a cardiovascular indication with significant medical need. This is stated in a press release. The planned transaction implies a pro forma value of SEK 365 to 405 million for the combined company, including a valuation of Hunter Captital RTO 1 of SEK 60 million, corresponding to SEK 1.33 per share. The valuation has been determined through negotiations between Hunter Capital RTO 1 and Resother Pharma and is considered to be in line with comparable transactions. It further means that existing shareholders will receive 15 percent of the combined company. Overall, the valuation is assessed to reflect the company's market value in the current transaction. The transaction is structured as a share transfer, whereby Resother Pharma becomes the listed company on Spotlight Stock Market.Resother Pharma intends, prior to completion of the transaction, to carry out a capital raise of SEK 80-120 million through a private placement in an unlisted environment, at a premoney valuation of SEK 225 million. With a capital raise of at least SEK 80 million, the financing is expected to be sufficient to enable completion and readout of the ongoing Phase 2a study, the conduct of a subsequent Phase 2b study, and to create conditions for potential M&A activities and partnerships. The financial runway is then expected to extend until mid-2028. The ambition is to complete the transaction no later than September 30.